Modality
mAb
MOA
TROP-2 ADC
Target
JAK2
Pathway
Complement
MigraineRCCSCLC
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
Sep 2022
→ Mar 2030
Phase 3Current
NCT05638685
1,047 pts·RCC
2022-09→TBD·Active
NCT05903686
387 pts·SCLC
2023-06→2030-03·Completed
NCT05012267
865 pts·SCLC
2025-11→2029-10·Terminated
2,299 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-10-193.6y awayPh3 Readout· SCLC
2030-03-063.9y awayPh3 Readout· SCLC
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2029-10-19 · 3.6y away
SCLC
Ph3 Readout
2030-03-06 · 3.9y away
SCLC
ActiveCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05638685 | Phase 3 | RCC | Active | 1047 | UPDRS |
| NCT05903686 | Phase 3 | SCLC | Completed | 387 | LiverFat |
| NCT05012267 | Phase 3 | SCLC | Terminated | 865 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |